Hospital at home model cuts acute care costs 38%

Hospital-level care at home can reduce overall care costs, healthcare use and readmissions while still providing quality care and improving the patient experience, according to a new study published in the Annals of Internal Medicine. The findings bolster the idea the idea acute care can be delivered outside traditional facilities and in lower-cost settings that are more beneficial to patients.

In fact, the hospital at home model saves 38% on an acute care episode compare to control patients in the study. Part of this savings came from lower healthcare use, with home patients receiving fewer laboratory orders, imaging studies and consultations.

Patient experience was also improved at home, with patients spending less time being sedentary compared to usual care patients––12% vs. 23% of the day––or lying down––18% vs. 55%. They were also readmitted less frequently within 30 days––7% compared to 23%.

Researchers from Brigham and Women's Hospital and Harvard Medical School conducted a randomized controlled trial, analyzing 91 patients––43 home and 48 control––admitted through the emergency department with selected acute conditions. The patients were recruited in the ED at Brigham and Women's Hospital and Brigham and Women's Faulkner Hospital, an academic medical center and a community hospital, respectively.

Patients in the home group were given a model of home visits with 24-hour physician coverage, twice-daily nurse visits and home-based treatments.

Researchers made note of the lower readmission rate among patients who received care at home.

“Perhaps patients who receive acute care at home are less likely to develop ‘posthospital syndrome’ because they sleep better; eat better; walk more; and become less deconditioned, malnourished and sedated,” wrote first author David M. Levine, MD, MPH, MA, an instructor in medicine at Brigham and Women’s Hospital, et al.

The researchers sought out to strengthen existing research that shows hospital at home models cost less, maintain quality and safety and improve patient experience. The study was limited with a small number of patients analyzed. It was also primarily paid for by Partners HealthCare Center for Population Health and internal departmental funds.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.